Filing Details

Accession Number:
0001240679-17-000035
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-09-06 17:34:01
Reporting Period:
2017-09-01
Accepted Time:
2017-09-06 16:34:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
806517 Psychemedics Corp PMD Services-Medical Laboratories (8071) 581701987
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1250730 I Michael Schaffer C/O Psychemedics Corporation
125 Nagog Park
Acton MA 01720
Vp Of Laboratory Operations No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $.005 Par Value Disposition 2017-09-01 981 $21.16 41,273 No 4 S Direct
Common Stock, $.005 Par Value Disposition 2017-09-05 4,400 $20.37 36,873 No 4 S Direct
Common Stock, $.005 Par Value Disposition 2017-09-06 2,167 $20.14 34,706 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.00 to $21.22, inclusive. The reporting person undertakes to provide to Psychemedics Corp., any security holder of Psychemedics Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.26 to $20.54, inclusive. The reporting person undertakes to provide to Psychemedics Corp., any security holder of Psychemedics Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
  3. Includes an additional 188 shares acquired since May 23, 2017 under the Company's Dividend Reinvestment Plan.